<?xml version='1.0' encoding='utf-8'?>
<document id="25017182"><sentence text="Pharmacokinetic interaction between rosuvastatin and olmesartan: a randomized, open-label, 3-period, multiple-dose crossover study in healthy Korean male subjects."><entity charOffset="36-48" id="DDI-PubMed.25017182.s1.e0" text="rosuvastatin" /><entity charOffset="53-63" id="DDI-PubMed.25017182.s1.e1" text="olmesartan" /><pair ddi="false" e1="DDI-PubMed.25017182.s1.e0" e2="DDI-PubMed.25017182.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25017182.s1.e0" e2="DDI-PubMed.25017182.s1.e1" /></sentence><sentence text="Rosuvastatin has been widely used in combination with olmesartan for the treatment of dyslipidemia accompanied by hypertension"><entity charOffset="0-12" id="DDI-PubMed.25017182.s2.e0" text="Rosuvastatin" /><entity charOffset="54-64" id="DDI-PubMed.25017182.s2.e1" text="olmesartan" /><pair ddi="false" e1="DDI-PubMed.25017182.s2.e0" e2="DDI-PubMed.25017182.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25017182.s2.e0" e2="DDI-PubMed.25017182.s2.e1" /></sentence><sentence text=" With no information currently available on the interaction between the 2 drugs, a pharmacokinetic study was conducted to investigate the influence of rosuvastatin on olmesartan and vice versa when the 2 drugs were coadministered"><entity charOffset="151-163" id="DDI-PubMed.25017182.s3.e0" text="rosuvastatin" /><entity charOffset="167-177" id="DDI-PubMed.25017182.s3.e1" text="olmesartan" /><pair ddi="false" e1="DDI-PubMed.25017182.s3.e0" e2="DDI-PubMed.25017182.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25017182.s3.e0" e2="DDI-PubMed.25017182.s3.e1" /></sentence><sentence text=" The purpose of this study was to investigate the pharmacokinetic profile of coadministration of the rosuvastatin 20-mg tablet and the olmesartan 40-mg tablet and the associated drug-drug interaction in healthy Korean male volunteers"><entity charOffset="101-113" id="DDI-PubMed.25017182.s4.e0" text="rosuvastatin" /><entity charOffset="135-145" id="DDI-PubMed.25017182.s4.e1" text="olmesartan" /><pair ddi="false" e1="DDI-PubMed.25017182.s4.e0" e2="DDI-PubMed.25017182.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25017182.s4.e0" e2="DDI-PubMed.25017182.s4.e1" /></sentence><sentence text="" /><sentence text="This was a randomized, open-label, 3-period, multiple-dose crossover study" /><sentence text=" Eligible subjects were aged 20 to 50 years and within 20% of their ideal body weight" /><sentence text=" After being randomly assigned to 6 groups of equal number, subjects received each of the following 3 formulations once a day for 7 consecutive days with an 8-day washout period between the formulations: rosuvastatin 20-mg tablet, olmesartan 40-mg tablet, and coadministration of the rosuvastatin 20-mg tablet and the olmesartan 40-mg tablet"><entity charOffset="204-216" id="DDI-PubMed.25017182.s8.e0" text="rosuvastatin" /><entity charOffset="231-241" id="DDI-PubMed.25017182.s8.e1" text="olmesartan" /><entity charOffset="284-296" id="DDI-PubMed.25017182.s8.e2" text="rosuvastatin" /><entity charOffset="318-328" id="DDI-PubMed.25017182.s8.e3" text="olmesartan" /><pair ddi="false" e1="DDI-PubMed.25017182.s8.e0" e2="DDI-PubMed.25017182.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25017182.s8.e0" e2="DDI-PubMed.25017182.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25017182.s8.e0" e2="DDI-PubMed.25017182.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25017182.s8.e0" e2="DDI-PubMed.25017182.s8.e3" /><pair ddi="false" e1="DDI-PubMed.25017182.s8.e1" e2="DDI-PubMed.25017182.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25017182.s8.e1" e2="DDI-PubMed.25017182.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25017182.s8.e1" e2="DDI-PubMed.25017182.s8.e3" /><pair ddi="false" e1="DDI-PubMed.25017182.s8.e2" e2="DDI-PubMed.25017182.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25017182.s8.e2" e2="DDI-PubMed.25017182.s8.e3" /></sentence><sentence text=" Blood samples were collected up to 72 hours after dosing, and pharmacokinetic parameters were determined for rosuvastatin, its active metabolite (N-desmethyl rosuvastatin), and olmesartan"><entity charOffset="110-122" id="DDI-PubMed.25017182.s9.e0" text="rosuvastatin" /><entity charOffset="146-171" id="DDI-PubMed.25017182.s9.e1" text="(N-desmethyl rosuvastatin" /><entity charOffset="178-188" id="DDI-PubMed.25017182.s9.e2" text="olmesartan" /><pair ddi="false" e1="DDI-PubMed.25017182.s9.e0" e2="DDI-PubMed.25017182.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25017182.s9.e0" e2="DDI-PubMed.25017182.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25017182.s9.e0" e2="DDI-PubMed.25017182.s9.e2" /><pair ddi="false" e1="DDI-PubMed.25017182.s9.e1" e2="DDI-PubMed.25017182.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25017182.s9.e1" e2="DDI-PubMed.25017182.s9.e2" /></sentence><sentence text=" Adverse events were evaluated based on subject interviews and physical examinations" /><sentence text="" /><sentence text="Among the 36 enrolled subjects, 34 completed the study (mean [range] age, 28" /><sentence text="6 [23-49] y; mean [range] weight, 66" /><sentence text="4 [52" /><sentence text="2-78" /><sentence text="7] kg)" /><sentence text=" The 90% CIs of the geometric mean ratios for the primary pharmacokinetic parameters for the coadministration of the 2 drugs to the mono-administration of each drug were 85" /><sentence text="14% to 96" /><sentence text="08% for AUCτ and 81" /><sentence text="41% to 97" /><sentence text="48% for Css,max for rosuvastatin, and 77"><entity charOffset="20-32" id="DDI-PubMed.25017182.s21.e0" text="rosuvastatin" /></sentence><sentence text="55% to 89" /><sentence text="48% for AUCτ and 75" /><sentence text="62% to 90" /><sentence text="12% for Css,max for N-desmethyl rosuvastatin; those values were 95"><entity charOffset="20-44" id="DDI-PubMed.25017182.s25.e0" text="N-desmethyl rosuvastatin" /></sentence><sentence text="61% to 102" /><sentence text="57% for AUCτ and 91" /><sentence text="73% to 102" /><sentence text="98% for Css,max for olmesartan"><entity charOffset="20-30" id="DDI-PubMed.25017182.s29.e0" text="olmesartan" /></sentence><sentence text=" Dizziness was the most frequently noted adverse drug reaction, occurring in 1 subject receiving mono-administration of rosuvastatin, 1 subject receiving mono-administration of olmesartan, and 4 subjects receiving coadministration of rosuvastatin and olmesartan"><entity charOffset="120-132" id="DDI-PubMed.25017182.s30.e0" text="rosuvastatin" /><entity charOffset="177-187" id="DDI-PubMed.25017182.s30.e1" text="olmesartan" /><entity charOffset="234-246" id="DDI-PubMed.25017182.s30.e2" text="rosuvastatin" /><entity charOffset="251-261" id="DDI-PubMed.25017182.s30.e3" text="olmesartan" /><pair ddi="false" e1="DDI-PubMed.25017182.s30.e0" e2="DDI-PubMed.25017182.s30.e0" /><pair ddi="false" e1="DDI-PubMed.25017182.s30.e0" e2="DDI-PubMed.25017182.s30.e1" /><pair ddi="false" e1="DDI-PubMed.25017182.s30.e0" e2="DDI-PubMed.25017182.s30.e2" /><pair ddi="false" e1="DDI-PubMed.25017182.s30.e0" e2="DDI-PubMed.25017182.s30.e3" /><pair ddi="false" e1="DDI-PubMed.25017182.s30.e1" e2="DDI-PubMed.25017182.s30.e1" /><pair ddi="false" e1="DDI-PubMed.25017182.s30.e1" e2="DDI-PubMed.25017182.s30.e2" /><pair ddi="false" e1="DDI-PubMed.25017182.s30.e1" e2="DDI-PubMed.25017182.s30.e3" /><pair ddi="false" e1="DDI-PubMed.25017182.s30.e2" e2="DDI-PubMed.25017182.s30.e2" /><pair ddi="false" e1="DDI-PubMed.25017182.s30.e2" e2="DDI-PubMed.25017182.s30.e3" /></sentence><sentence text=" All the adverse events were expected, and there was no significant difference in the incidence between the 2 formulations" /><sentence text="" /><sentence text="This study suggests that rosuvastatin and olmesartan did not significantly influence each other's pharmacokinetics when coadministered"><entity charOffset="25-37" id="DDI-PubMed.25017182.s33.e0" text="rosuvastatin" /><entity charOffset="42-52" id="DDI-PubMed.25017182.s33.e1" text="olmesartan" /><pair ddi="false" e1="DDI-PubMed.25017182.s33.e0" e2="DDI-PubMed.25017182.s33.e0" /><pair ddi="false" e1="DDI-PubMed.25017182.s33.e0" e2="DDI-PubMed.25017182.s33.e1" /></sentence><sentence text=" Although the pharmacokinetics of N-desmethyl rosuvastatin were influenced by olmesartan, such interactions were considered clinically insignificant"><entity charOffset="34-58" id="DDI-PubMed.25017182.s34.e0" text="N-desmethyl rosuvastatin" /><entity charOffset="78-88" id="DDI-PubMed.25017182.s34.e1" text="olmesartan" /><pair ddi="false" e1="DDI-PubMed.25017182.s34.e0" e2="DDI-PubMed.25017182.s34.e0" /><pair ddi="false" e1="DDI-PubMed.25017182.s34.e0" e2="DDI-PubMed.25017182.s34.e1" /></sentence><sentence text=" All 3 formulations were well tolerated, and no serious adverse events or drug reactions were noted" /><sentence text="" /></document>